ArticleNature communications2019
An MPER antibody neutralizes HIV-1 using germline features shared among donors.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 58 citations in OpenAlex.
- Structural basis of membrane engagement and polyreactivity control in HIV-1 MPER broadly neutralizing antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Virus glycoprotein nanodisc platform for vaccine analytics.Nature communications · 2026Article
- Heterologous immunization modulates B-cell epitope competition between helper peptides and the MPER segment in MPER/liposome vaccines.NPJ vaccines · 2026Article
- Germline-Targeting Strategies to Induce bNAbs against HIV-1.Current HIV research · 2026Review
- Article
- Distinctive Membrane Accommodation Traits Underpinning the Neutralization Activity of HIV-1 Antibody against MPER.Molecular pharmaceutics · 2025Article
- Article
- Isolation and structure of broad SIV-neutralizing antibodies reveal a proximal helical MPER epitope recognized by a rhesus multi-donor class.Cell reports · 2025Article
- Structural development of the HIV-1 apex-directed PGT145-PGDM1400 antibody lineage.Cell reports · 2025Article
- Viral glycoprotein-mediated entry and antibody-mediated immunity in HIV-1 and SARS-CoV-2 infection.Frontiers in immunology · 2025Review
- Generation of a Nonbilayer Lipid Nanoenvironment after Epitope Binding Potentiates Neutralizing HIV-1 MPER Antibody.ACS applied materials & interfaces · 2024Article
- Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1.Journal of biomedical science · 2024Review
- Affinity gaps among B cells in germinal centers drive the selection of MPER precursors.Nature immunology · 2024Article
- Vaccination induces broadly neutralizing antibody precursors to HIV gp41.Nature immunology · 2024Article
- Inadequate structural constraint on Fab approach rather than paratope elicitation limits HIV-1 MPER vaccine utility.Nature communications · 2023Article
- Partial compartmentalisation of HIV-1 subtype C between lymph nodes, peripheral blood mononuclear cells and plasma.Virology · 2023Article
- Neutralization Sensitivity and Evolution of Virus in a Chronic HIV-1 Clade B Infected Patient with Neutralizing Activity against Membrane-Proximal External Region.Pathogens (Basel, Switzerland) · 2023Article
- Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies.Nature reviews. Immunology · 2023Review
- Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection.Vaccines · 2023Review
- Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies.Journal of virology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 10 institutions in 11 countries.
Lei ZhangDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, 92037, USA.
Adriana IrimiaDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, 92037, USA.
Lingling HeDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, 92037, USA.
Elise LandaisDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, 92037, USA.
Kimmo RantalainenDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, 92037, USA.
Daniel P LeamanDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, 92037, USA.
Thomas VollbrechtDepartment of Medicine, University of California, San Diego, California, 92093, USA.ORCID http://orcid.org/0000-0003-1151-8844
Armando StanoDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, 92037, USA.
Daniel I SandsDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, 92037, USA.ORCID http://orcid.org/0000-0001-6880-7036
Arthur S KimDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, 92037, USA.ORCID http://orcid.org/0000-0003-4101-6642
IAVI Protocol G Investigators
Pascal PoignardDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, 92037, USA.
Dennis R BurtonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, 92037, USA.ORCID http://orcid.org/0000-0001-6711-9864
Ben MurrellDepartment of Medicine, University of California, San Diego, California, 92093, USA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, 92037, USA.ORCID http://orcid.org/0000-0001-7153-3769
Jiang ZhuDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, 92037, USA. jiang@scripps.edu.
Ian A WilsonDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, 92037, USA. wilson@scripps.edu.ORCID http://orcid.org/0000-0002-6469-2419
Michael B ZwickDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, 92037, USA. zwick@scripps.edu.
Scripps Research Institute · USEmory University · USDesmond Tutu HIV Foundation · ZAEmory and Henry College · USSt Stephen’s AIDS Trust · GBUganda Virus Research Institute · UGUniversity of Nairobi · KEInternational AIDS Vaccine Initiative · USMahidol University · THUniversity of California San Diego · US
Funding
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6MSupport Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5MUC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3MVirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4MX-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6MPushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogensP01AI124337 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI ZHU, JIANG · 2016 to 2020
$12.2MUncleaved prefusion-optimized trimers on nanoparticles as HIV vaccinesR01AI140844 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZHU, JIANG · 2019 to 2023
$4.9MHIV-1 vaccine design emphasizing bnAb targets on membrane Env liposomesR01AI143563 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZWICK, MICHAEL B · 2019 to 2023
$4.0MRational design and B cell responses of HIV epitope vaccinesR01AI129698 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZHU, JIANG · 2017 to 2021
$3.2MEliciting antibodies to probe native trimeric gp41 for HIV vaccine designR01AI114401 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZWICK, MICHAEL B · 2014 to 2018
$2.9MHIV-1 vaccine design emphasizing bnAb targets on membrane Env liposomesR56AI143563 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZWICK, MICHAEL B · 2019 to 2019
$292kNCATS NIH HHS UL1 TR001442NIAID NIH HHS P01 AI124337NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI114401NIAID NIH HHS R01 AI129698NIAID NIH HHS R01 AI140844NIAID NIH HHS R01 AI143563NIAID NIH HHS R56 AI143563NIAID NIH HHS UM1 AI100663NIAID NIH HHS UM1 AI144462NIGMS NIH HHS P41 GM103393
Abstract
The membrane-proximal external region (MPER) of HIV-1 envelope glycoprotein (Env) can be targeted by neutralizing antibodies of exceptional breadth. MPER antibodies usually have long, hydrophobic CDRH3s, lack activity as inferred germline precursors, are often from the minor IgG3 subclass, and some are polyreactive, such as 4E10. Here we describe an MPER broadly neutralizing antibody from the major IgG1 subclass, PGZL1, which shares germline V/D-region genes with 4E10, has a shorter CDRH3, and is less polyreactive. A recombinant sublineage variant pan-neutralizes a 130-isolate panel at 1.4 μg/ml (IC
Indexed as
Antibodies, MonoclonalAntibodies, NeutralizingCell MembraneCryoelectron MicroscopyCrystallography, X-RayDrug Resistance, ViralEpitopesHIV-1HIV Envelope Protein gp41HumansHydrophobic and Hydrophilic InteractionsImmunoglobulin Fab FragmentsImmunoglobulin GProtein ConformationAntibodies, MonoclonalAntibodies, NeutralizingEpitopesHIV Envelope Protein gp41Immunoglobulin Fab FragmentsImmunoglobulin G
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.